✉ Email this page to a colleague
« Back to Dashboard
GDC-0917 is an investigational drug.
There have been 184 clinical trials for GDC-0917. The most recent clinical trial was a Phase 3 trial, which was initiated on October 27th 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are twelve US patents protecting this investigational drug and one hundred and ninety-five international patents.
Recent Clinical Trials for GDC-0917
|Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
|Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL||Kazia Therapeutics Limited||Phase 2|
Top disease conditions for GDC-0917
Top clinical trial sponsors for GDC-0917
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GDC-0917||See Plans and Pricing||Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy||SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (La Jolla, CA) SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla, CA)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||SMC combination therapy for the treatment of cancer||Children's Hospital of Eastern Ontario Research Institute Inc. (Ottawa, ON, CA)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||Benzolactam compounds as protein kinase inhibitors||OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity||ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity||ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||Modulators of estrogen receptor proteolysis and associated methods of use||ARVINAS OPERATIONS, INC. (New Haven, CT)||See Plans and Pricing|
|GDC-0917||See Plans and Pricing||Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders||Arvinas Operations, Inc. (New Haven, CT)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GDC-0917||Canada||CA2950911||2034-06-04||See Plans and Pricing|
|GDC-0917||European Patent Office||EP3151920||2034-06-04||See Plans and Pricing|
|GDC-0917||Japan||JP2017522273||2034-06-04||See Plans and Pricing|
|GDC-0917||Japan||JP2020125302||2034-06-04||See Plans and Pricing|
|GDC-0917||Japan||JP6768522||2034-06-04||See Plans and Pricing|
|GDC-0917||World Intellectual Property Organization (WIPO)||WO2015187998||2034-06-04||See Plans and Pricing|
|GDC-0917||Canada||CA2974651||2034-01-24||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|